Benjamin Corb, public affairs director for the American Society for Biochemistry and Molecular Biology (ASBMB), discusses what the biomedical research community can expect from the incoming administration of Donald J. Trump.

Previous articleJ&J, NYS and NY Genome Center Collaborate to Launch JLABS @ NYC
Next articleFosun, Daiichi Sankyo Ink Deals for Kite’s CAR T-Cell Therapy in China and Japan